Issues in comparisons between meta-analyses and large trials

JAMA

Volumn 279, Issue 14, 1998, Pages 1089-1093

  Ioannidis, John P A ^a   Cappelleri, Joseph C ^b   Lau, Joseph ^c  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; META ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; QUALITY CONTROL;

EID: 0032495819     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.279.14.1089     Document Type: Article

References (48)

1. Chalmers TC, Lau J. Changes in clinical trials mandated by the advent of meta-analysis. Stat Med. 1996; 15:1263-1268.
2. Borzak S, Ridker PM. Discordance between meta-analyses and large-scale randomized, controlled trials. Ann Intern Med. 1995;123:873-877.
3. Bailar JC III. The promise and problems of meta-analysis. N Engl J Med. 1997;337:559-561.
4. Naylor CD. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 1997;315:617-619.
5. Meta-analysis under scrutiny [editorial]. Lancet. 1997;350:675.
6. Villar J, Carroli G, Belizan JM. Predictive ability of meta-analyses of randomised controlled trials. Lancet. 1995;345:772-776.
7. Cappelleri JC, Ioannidis JPA, Schmid CH, et al. Large trials vs meta-analyses of small trials: how do their results compare? JAMA. 1996;276:1332-1338.
8. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536-542.
9. Ioannidis JP, Cappelleri JC, Lau J. Meta-analyses and large randomized, controlled trials. N Engl J Med. 1998;338:59.
10. LeLorier J, Gregoire G. Meta-analyses and large randomized, controlled trials. N Engl J Med. 1998;338: 61-62.
11. Bailar JC III. Meta-analyses and large randomized, controlled trials. N Engl J Med. 1998;338:62.
12. Enkin MW, Keirse NC, Renfrew MJ, Neilson JP, eds. Pregnancy and Childhood Module: Cochrane Database of Systematic Reviews (Cochrane Updates on Disk). Oxford, England: Update Software; 1996.
13. Ioannidis JP, Cappelleri JC, Sacks HS, Lau J. The relationship of study design, results, and reporting of randomized clinical trials of HIV infection. Control Clin Trials. 1997;18:431-444.
14. Cappelleri JC, Ioannidis JP, Lau J. Meta-analyses and large trials [letter]. JAMA. 1997;277:377-378.
15. Ioannidis JP, Bassett R, Hughes MD, Volberding P, Sacks HS, Lau J. Predictors and impact of patients lost to follow-up in a randomized trial of immediate versus deferred antiretroviral treatment. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:22-30.
16. Lakatos E. Sample size determination in clinical trials with time-dependent rates of losses and noncompliance. Control Clin Trials. 1986;7:189-199.
17. Woods KL. Mega-trials and management of acute myocardial infarction. Lancet. 1995;346:611-614.
18. Yusuf S, Collins R, Peto R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409-422.
19. Ioannidis JP, Lau J. On meta-analyses of meta-analyses. Lancet. 1996;348:756.
20. Goodman SN. P values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate. Am J Epidemiol. 1993;137:486-496.
21. Rothman K. A show of confidence. N Engl J Med. 1978;299:1362-1363.
22. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
23. Cytel Software Corp. StatXact, Version S: Statistical Software for Exact Non-parametric Inference. Cambridge, Mass: Cytel Software Corp; 1995.
24. Cohen J. Weighted kappa: nominal scale agreement with provision for scale disagreement or partial credit. Psychol Bull. 1968;70:213-220.
25. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1-30.
26. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;126: 820-826.
27. Deeks JJ, Altman DG, Dooley G, Sackett DLS. Choosing an appropriate dichotomous effect measure for meta-analysis. Control Clin Trials. 1997;18:84S-85S.
28. Horwitz RI. Complexity and contradiction in clinical trial research. Am J Med. 1987;82:498-510.
29. Cook DJ, Guyatt GH, Laupacis A, Sackett DL, Goldberg RJ. Clinical recommendations using level of evidence for antithrombotic agents. Chest. 1995;108:227S-230S.
30. McIntosh MW. The population risk as an explanatory variable in research synthesis of clinical trials. Stat Med. 1996;15:1713-1728.
31. Schmid CH, Lau J, McIntosh M, Cappelleri JC. An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. Stat Med. In press.
32. Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ. 1996;313:735-738.
33. Morgenstern H. Uses of ecologic analysis in epidemiologic research. Am J Public Health. 1982;72:1336-1344.
34. Ioannidis JP, Lau J. The impact of high risk patients on the results of clinical trials. J Clin Epidemiol. 1997; 50:1089-1098.
35. Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med. 1993;118:99-105.
36. Dickersin K, Chan S, Chalmers TC, Sacks HS, Smith H Jr. Publication bias and clinical trials. Control Clin Trials. 1987;8:343-353.
37. Begg CB, Mazumdar M. Operating characterisitcs of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
38. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a single, graphical test. BMJ. 1997;315:629-634.
39. Lau J, Ioannidis JPA, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1997; 351:123-127.
40. Ioannidis JP, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. Am J Epidemiol. 1996;144:1074-1085.
41. Horwitz RI, Singer BH, Makuch RW, Viscoli CM. Can treatment that is helpful on average by harmful to some patients? J Clin Epidemiol. 1996;49:395-400.
42. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acute myocardial infarction. Lancet. 1992;339:1553-1558.
43. Berlin JA, Antman EM. Advantages and limitations of metaanalytic regressions of clinical trials data. Online J Curr Clin Trials [serial online]. June 4, 1994; doc 134.
44. Stewart LA, Clarke MJ, and the Cochrane Working Group. Practical methodology of meta-analyses (overviews) using updated individual patient data. Stat Med. 1995;14:2057-2079.
45. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. JAMA. 1996;276:637-639.
46. Moher D, Olkin I. Meta-analysis of randomized controlled trials: a concern for standards. JAMA. 1995;274: 1962-1964.
47. Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA 1998;351:319-320.
48. Pogue J, Yusuf S. Overcoming the limitations of current meta-analysis of randomised controlled trials. Lancet. 1998;351:42-47.